Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17676502 | 0.91 | GRM2 (0.43) | MAOBGRM2 | |
| SCHEMBL3209052 | 0.88 | CALML3 (0.50) | CALML3MAOAMAOBGRM2CYP2C19 | |
| SCHEMBL3197109 | 0.88 | CALML3 (0.50) | CALML3MAOAMAOBGRM2CYP2C19 | |
| SCHEMBL14387034 | 0.87 | GRM2 (0.44) | MAOBGRM2 | |
| SCHEMBL13486332 | 0.87 | GRM2 (0.39) | MAOBGRM2 | |
| SCHEMBL3200347 | 0.86 | CALML3 (0.52) | CALML3MAOAMAOB | |
| SCHEMBL13486335 | 0.81 | IL6 (0.38) | CYP3A4 | |
| SCHEMBL3205152 | 0.79 | GRM2 (0.48) | CALML3GRM2 | |
| SCHEMBL3198649 | 0.78 | CALML3 (0.46) | CALML3 | |
| SCHEMBL3198798 | 0.76 | GRM2 (0.49) | CALML3MAOBGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | FAB PHARMA (FR) | 2016-06-30 | — | — | US | disclosed |
| US-9309179-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA (FR) | 2016-04-12 | — | — | US | disclosed |
| US-8722746-B2 | Hydroxyphenyl derivatives and biological applications thereof | FAB PHARMA S.A.S. (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | FAB PHARMA (FR) | 2010-02-18 | — | — | US | disclosed |
| WO-2007135562-A2 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS S.A. (FR) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041658-A1 | Hydroxyphenyl Derivatives and Biological Applications Thereof | HPD, HPGDS, EPX | CALML3 3469/4885MAOA 1013/4885MAOB 784/4885 |
| US-20160185724-A1 | HYDROXYPHENYL DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | HPD, HPGDS, EPX | CALML3 3469/4885MAOA 1013/4885MAOB 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.